Barbe M, Batra A, Golding S, Hammond O, Higgins JC, O’Connor A, Vlahovic TC (2021) Pyoderma gangrenosum: a literature review. Clin Podiatr Med Surg 38(4):577–588. https://doi.org/10.1016/j.cpm.2021.06.002

Article  PubMed  Google Scholar 

Maronese CA, Pimentel MA, Li MM, Genovese G, Ortega-Loayza AG, Marzano AV (2022) Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments. Am J Clin Dermatol 23(5):615–634. https://doi.org/10.1007/s40257-022-00699-8

Article  PubMed  PubMed Central  Google Scholar 

Flora A, Kozera E, Frew JW (2022) Pyoderma gangrenosum: a systematic review of the molecular characteristics of disease. Exp Dermatol 31(4):498–515. https://doi.org/10.1111/exd.14534

Article  PubMed  Google Scholar 

George C, Deroide F, Rustin M (2019) Pyoderma gangrenosum—a guide to diagnosis and management. Clin Med 19(3):224–228. https://doi.org/10.7861/clinmedicine.19-3-224

Article  Google Scholar 

Welsch K, Holstein J, Laurence A, Ghoreschi K (2017) Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol 47(7):1096–1107. https://doi.org/10.1002/eji.201646680

Article  CAS  PubMed  Google Scholar 

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31(11):1409–1417. https://doi.org/10.1007/s00296-011-1999-3

Article  PubMed  Google Scholar 

Kim HS, Kwon JE, Park YJ (2023) Atezolizumab plus bevacizumab-induced recalcitrant pyoderma gangrenosum treated with baricitinib: a case report. Acta Derm Venereol 103:adv9646. https://doi.org/10.2340/actadv.v103.9646

Article  PubMed  Google Scholar 

Scheinberg M, Machado LA, Castro LGM, Ferreira SB, Michalany N (2021) Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor. J Transl Autoimmun 4:100099. https://doi.org/10.1016/j.jtauto.2021.100099

Article  CAS  PubMed  PubMed Central  Google Scholar 

Castro LGM (2023) JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum. Int J Dermatol 62(8):1088–1093. https://doi.org/10.1111/ijd.16676

Article  CAS  PubMed  Google Scholar 

Sathyanarayana VA, Roy D, Nagaraju B, Rao VKR (2023) Tofacitinib in pyoderma gangrenosum—a case series. Int J Rheum Dis. https://doi.org/10.1111/1756-185X.14810

Article  PubMed  Google Scholar 

Gregory MH, Ciorba MA, Deepak P, Christophi GP (2019) Successful treatment of pyoderma gangrenosum with concomitant tofacitinib and infliximab. Inflamm Bowel Dis 25(7):e87–e88. https://doi.org/10.1093/ibd/izz015

Article  PubMed  Google Scholar 

Salmón Olavarría P, Rubio Iturria S, Nantes Castillejo Ó (2021) Tofacitinib, a useful option for the treatment of pyoderma gangrenosum in an ulcerative colitis patient. Rev Esp Enferm Dig 113(10):733–734. https://doi.org/10.17235/reed.2021.7977/2021

Article  PubMed  Google Scholar 

Sedano R, Jairath V (2021) Tofacitinib for the treatment of three immune-mediated conditions in one patient: ulcerative colitis, pyoderma gangrenosum, and alopecia areata. Inflamm Bowel Dis 27(5):e65. https://doi.org/10.1093/ibd/izab005

Article  PubMed  Google Scholar 

Van Eycken L, Dens AC, de Vlam K, Neerinckx B, De Haes P (2023) Resolution of therapy-resistant pyoderma gangrenosum with upadacitinib. JAAD Case Rep 37:89–91. https://doi.org/10.1016/j.jdcr.2023.05.016

Article  PubMed  PubMed Central  Google Scholar 

Dos Santos MR, Ianhez M, Ribeiro BN, de Queiroz BB, Miot HA (2023) Refractory pyoderma gangrenosum associated with rheumatoid arthritis successfully treated with upadacitinib. Comments on: “JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum.” Int J Dermatol 62(11):e595–e598. https://doi.org/10.1111/ijd.16791

Article  CAS  PubMed  Google Scholar 

Rahbar Kooybaran N, Korsten P, Schön MP, Mössner R (2022) Ansprechen eines mit rheumatoider arthritis assoziierten pyoderma gangraenosum auf den JAK1-inhibitor upadacitinib. J Dtsch Dermatol Ges 20(4):522–524. https://doi.org/10.1111/ddg.14716_g

Article  PubMed  Google Scholar 

Shanmugam VK, McNish S, Shara N, Hubley KJ, Kallakury B, Dunning DM, Attinger CE, Steinberg JS (2013) Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi(®)). J Foot Ankle Surg 52(6):781–785. https://doi.org/10.1053/j.jfas.2013.07.003

Article  PubMed  PubMed Central  Google Scholar 

Nasifoglu S, Heinrich B, Welzel J (2018) Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor. Br J Dermatol 179(2):504–505. https://doi.org/10.1111/bjd.16468

Article  CAS  PubMed  Google Scholar 

Choi AW, Abuav R, Rabizadeh SM, Ansari R, Marsch AF (2020) Recalcitrant and severe pyoderma gangrenosum attributable to levamisole-adulterated cocaine and treated successfully with oral tofacitinib. JAAD Case Rep 6(9):939–941. https://doi.org/10.1016/j.jdcr.2020.07.035

Article  PubMed  PubMed Central  Google Scholar 

Kochar B, Herfarth N, Mamie C, Navarini AA, Scharl M, Herfarth HH (2019) Tofacitinib for the treatment of pyoderma gangrenosum. Clin Gastroenterol Hepatol 17(5):991–993. https://doi.org/10.1016/j.cgh.2018.10.047

Article  PubMed  Google Scholar 

Sitaru S, Biedermann T, Lauffer F (2022) Successful treatment of pyoderma gangrenosum with Janus kinase 1/2 inhibition. JEADV Clin Pract 1(4):420–423. https://doi.org/10.1002/jvc2.62

Article  Google Scholar 

Bhowmick K, Roongta R, Dey S, Dey S, Mondal S, Sinhamahapatra P, Ghosh P, Ghosh B (2023) Refractory Takayasu arteritis with recurrent pyoderma gangrenosum: a therapeutic challenge with case-based review. Clin Rheumatol 42(5):1469–1477. https://doi.org/10.1007/s10067-023-06506-x

Article  PubMed  Google Scholar 

Orfaly VE, Kovalenko I, Tolkachjov SN, Ortega-Loayza AG, Nunley JR (2021) Tofacitinib for the treatment of refractory pyoderma gangrenosum. Clin Exp Dermatol 46(6):1082–1085. https://doi.org/10.1111/ced.14683

Article  CAS  PubMed  Google Scholar 

Ahronowitz I, Harp J, Shinkai K (2012) Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol 13(3):191–211. https://doi.org/10.2165/11595240-000000000-00000

Article  PubMed  Google Scholar 

Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J, Mason JM, Walton S, Johnston GA, Williams HC, UK Dermatology Clinical Trials Network’s STOP GAP Team (2015) Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ 350:h2958. https://doi.org/10.1136/bmj.h2958

Article  PubMed  PubMed Central  Google Scholar 

Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, Forbes A, Greenwood R, Probert CS (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55(4):505–509. https://doi.org/10.1136/gut.2005.074815

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dissemond J, Marzano AV, Hampton PJ, Ortega-Loayza AG (2023) Pyoderma gangrenosum: treatment options. Drugs 83(14):1255–1267. https://doi.org/10.1007/s40265-023-01931-3

Article  PubMed  PubMed Central  Google Scholar 

Ben Abdallah H, Fogh K, Bech R (2019) Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: a semi-systematic review. Int Wound J 16(2):511–521. https://doi.org/10.1111/iwj.13067

Article  PubMed  PubMed Central  Google Scholar 

Ben Abdallah H, Fogh K, Vestergaard C, Bech R (2022) Pyoderma gangrenosum and interleukin inhibitors: a semi-systematic review. Dermatology 238(4):785–792. https://doi.org/10.1159/000519320

Article  CAS  PubMed